486 related articles for article (PubMed ID: 16001166)
1. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
Zhou Q; Olivo M; Lye KY; Moore S; Sharma A; Chowbay B
Cancer Chemother Pharmacol; 2005 Dec; 56(6):569-77. PubMed ID: 16001166
[TBL] [Abstract][Full Text] [Related]
2. Effect of hypericin-mediated photodynamic therapy on the expression of vascular endothelial growth factor in human nasopharyngeal carcinoma.
Bhuvaneswari R; Gan YY; Yee KK; Soo KC; Olivo M
Int J Mol Med; 2007 Oct; 20(4):421-8. PubMed ID: 17786271
[TBL] [Abstract][Full Text] [Related]
3. Combined antiangiogenic and immune therapy of prostate cancer.
Huang X; Raskovalova T; Lokshin A; Krasinskas A; Devlin J; Watkins S; Wolf SF; Gorelik E
Angiogenesis; 2005; 8(1):13-23. PubMed ID: 16132614
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma.
Ferrario A; von Tiehl KF; Rucker N; Schwarz MA; Gill PS; Gomer CJ
Cancer Res; 2000 Aug; 60(15):4066-9. PubMed ID: 10945611
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
[TBL] [Abstract][Full Text] [Related]
6. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington
Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623
[TBL] [Abstract][Full Text] [Related]
7. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response.
Griffin RJ; Williams BW; Wild R; Cherrington JM; Park H; Song CW
Cancer Res; 2002 Mar; 62(6):1702-6. PubMed ID: 11912143
[TBL] [Abstract][Full Text] [Related]
9. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R
Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140
[TBL] [Abstract][Full Text] [Related]
10. Irradiation combined with SU5416: microvascular changes and growth delay in a human xenograft glioblastoma tumor line.
Schuuring J; Bussink J; Bernsen HJ; Peeters W; van Der Kogel AJ
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):529-34. PubMed ID: 15667976
[TBL] [Abstract][Full Text] [Related]
11. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
Ning S; Laird D; Cherrington JM; Knox SJ
Radiat Res; 2002 Jan; 157(1):45-51. PubMed ID: 11754641
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution and photodynamic therapy with hypericin in a human NPC murine tumor model.
Du HY; Bay BH; Olivo M
Int J Oncol; 2003 May; 22(5):1019-24. PubMed ID: 12684667
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic agent SU6668 suppresses the tumor growth of xenografted A-431 cells.
Nakamura T; Ozawa S; Kitagawa Y; Ueda M; Kubota T; Kitajima M
Oncol Rep; 2006 Jan; 15(1):79-83. PubMed ID: 16328037
[TBL] [Abstract][Full Text] [Related]
14. Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma.
Yee KK; Soo KC; Olivo M
Int J Mol Med; 2005 Dec; 16(6):993-1002. PubMed ID: 16273277
[TBL] [Abstract][Full Text] [Related]
15. [Photosensitizer nanoparticles photodynamic therapy on LOVO human colon cancer xenografts in athymic mice].
Qing SH; Li LY; Sheng XH; Ba MC
Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Nov; 9(6):530-3. PubMed ID: 17143803
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo.
Klenke FM; Abdollahi A; Bertl E; Gebhard MM; Ewerbeck V; Huber PE; Sckell A
BMC Cancer; 2007 Mar; 7():49. PubMed ID: 17367541
[TBL] [Abstract][Full Text] [Related]
17. Expression of Y-Box binding protein-1 following hypericin-mediated photodynamic therapy in well-differentiated nasopharyngeal cancer in vivo.
Du HY; Olivo M; Chen YJ; Yip G; Tan PH; Matsumoto K; Tsujimoto M; Bay BH
Int J Mol Med; 2005 Nov; 16(5):865-8. PubMed ID: 16211256
[TBL] [Abstract][Full Text] [Related]
18. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
[TBL] [Abstract][Full Text] [Related]
19. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice.
Laird AD; Christensen JG; Li G; Carver J; Smith K; Xin X; Moss KG; Louie SG; Mendel DB; Cherrington JM
FASEB J; 2002 May; 16(7):681-90. PubMed ID: 11978732
[TBL] [Abstract][Full Text] [Related]
20. Hypericin-mediated photodynamic therapy in combination with Avastin (bevacizumab) improves tumor response by downregulating angiogenic proteins.
Bhuvaneswari R; Yuen GY; Chee SK; Olivo M
Photochem Photobiol Sci; 2007 Dec; 6(12):1275-83. PubMed ID: 18046482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]